Boehringer Ingelheim’s sodium-glucose co-transporter 2
(SGLT-2) inhibitor, JardianceÒ (empagliflozin),
has been announced winner of the 2018 Prix Galien International Award in the
category “Best Pharmaceutical Product”.

The Prix Galien Award is presented by the Galien Foundation
to recognise and reward excellence in scientific innovation and outstanding
achievement in improving the human condition through the development of
innovative therapies. It is counted among the global health innovation
industry’s most prized honours, and worldwide is regarded as the equivalent of
the Nobel prize in biopharmaceutical and medical technology research. The
nominees, selected by an independent committee of distinguished researchers and
academics, must demonstrate tremendous potential to impact human health.

Winners of the Prix Galien Award were announced last month at
an inaugural event in Dakar, Senegal; the first time the annual award has been
presented on the African continent. JardianceÒ was selected from among 20 other innovative nominees,
representing advancements in diabetes, spinal muscular atrophy and acquired
immunodeficiency syndrome.

The SGLT-2 inhibitors are a relatively new class of
glucose-lowering agents and have been shown to confer significant benefits in
terms of cardiovascular outcomes in patients with type 2 diabetes.

“We are thrilled that the international community has
recognised the benefits of Jardiance”, says Dr Michael Klein, Medical Director
of Boehringer Ingelheim, South Africa. “Presentation of the award on African
soil this year is particularly fitting and representative of our sincere
commitment to health and wellbeing of the peoples of South Africa and the
continent in general.”

Source: Boehringer
Ingelheim